Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

Item

http://www.wikidata.org/entity/Q37358508

Q37358508

about

Human CalDAG-GEFI gene (RASGRP2) mutation affects platelet function and causes severe bleeding Key role of glycoprotein Ib/V/IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay Binding of thrombin-activated platelets to a fibrin scaffold through α(IIb)β₃ evokes phosphatidylserine exposure on their cell surface The C-terminal CGHC motif of protein disulfide isomerase supports thrombosis.Clinical use of new antithrombotic therapies for medical management of acute coronary syndromes Abciximab does not inhibit the increase of thrombin generation produced in platelet-rich plasma in vitro by sodium arachidonate or tissue factor Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system.Shedding of procoagulant microparticles from unstimulated platelets by integrin-mediated destabilization of actin cytoskeleton.WASP plays a novel role in regulating platelet responses dependent on alphaIIbbeta3 integrin outside-in signalling Procoagulant profile in patients with immune thrombocytopenia.Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges.Protein 4.1R-deficient mice are viable but have erythroid membrane skeleton abnormalities.Glycoprotein IIb/IIIa and P2Y12 induction by oligochitosan accelerates platelet aggregation.Potential role for rFVIIa in transfusion medicine.A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab: Reopro) coated stent in patients with coronary artery disease.Long-term clinical benefits of a platelet glycoprotein IIb/IIIa receptor blocker, abciximab (ReoPro), in high-risk diabetic patients undergoing percutaneous coronary intervention.Acute vertebrobasilar occlusion: current treatment strategies.Integrin-dependent control of translation: engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets.Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice.Platelet-dependent thrombography gives a distinct pattern of in vitro thrombin generation after surgery with cardio-pulmonary bypass: potential implications.beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.Characterizing blood microparticles: technical aspects and challenges.A bumpy and winding but right path to domestic drug-eluting coronary stents.Structural and mechanistic insight into how antibodies inhibit serine proteases.Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by beta3 integrins.Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics Past, present, and future of anti-platelet therapy.Monocytes regulate systemic coagulation and inflammation in abdominal sepsis.Impaired alpha(IIb)beta(3) integrin activation and shear-dependent thrombus formation in mice lacking phospholipase D1.Key role of integrin α(IIb)β (3) signaling to Syk kinase in tissue factor-induced thrombin generation.Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year.Greater inhibition of platelet procoagulant activity by antibody-derived glycoprotein IIb--IIIa inhibitors than by peptide and peptidomimetic inhibitors.Platelets inhibit the lysis of pulmonary microemboli.

P2860

Q24299751-432400C2-FE3D-4017-AF34-F46C97C22FD9 Q24305071-F0F4CAE6-D39C-4DBC-A481-DB15F15C27FC Q24793321-5B6123C4-CBC1-4913-AB7A-F5343C692416 Q24812269-6BA6FE06-1ED8-45A6-B81F-B5B7AF5EB79C Q27316701-BC8C7D51-8EE0-4120-B737-AE8CAF1E7756 Q27332350-07320F33-D1FF-4A72-AB5A-41C252EE6CA0 Q28177271-5934A9B4-1099-4F7B-B658-FBAAA52A1F4F Q28183647-6053F2D0-3FE1-43A6-9054-32E6F44EDCD5 Q28189075-CD850D19-58EA-4563-B791-7D525DB6A001 Q28199325-558775E8-3683-4724-A737-4138DB3F659C Q28214135-02D2FBE6-2B70-490E-951C-B1F8EB4C5150 Q33338284-963A954D-B6C3-4FF5-8574-26BEF1249068 Q33372685-FE3FD2AB-CEDE-4E74-8033-5C044FE09FF1 Q33386825-3CD5D81F-AE64-455A-B621-15F65F3430D3 Q33436189-48569A4E-17F7-4595-B609-BAAD8BDA9443 Q33615785-ED5BC2FB-C9D7-4E42-BFFA-09CE078533B8 Q33835575-23E37619-DE9F-4EAF-B8BC-04ECD682AB5F Q34176926-75F074BD-41A2-423D-8869-FFA214E779D0 Q34564930-E4D03E1B-0FFE-4BF7-8855-202C5776B648 Q35849995-7D79DCCD-1AFA-4034-B3AB-418BD07A78DB Q35936923-50B49935-5B90-4D29-93FD-0C6F80B4F5E8 Q35937178-5E472689-AFED-44D8-8902-CD6EA68435E0 Q36273731-9C9ED9AE-3C6D-413B-9FB4-A0E6503EE5A3 Q36288115-3B8BC47C-2A83-4648-97E1-9146F4F41992 Q36376147-5B0E5F76-5139-4EAE-AFE0-9DE9C8B6ACF8 Q36467593-D7CB639B-B579-4854-B38D-EBCC6032F387 Q36507782-13F211ED-AA3D-4319-AB64-8FC6FBE7CCF7 Q36536184-8A04674F-83CD-4A48-9BAE-6D99DBBEF5D2 Q37004064-88E52375-C3FC-4E83-8DB2-D467B9DB2D4D Q37316783-193DCAB3-744D-48DD-A45C-DB704EA321EC Q37779571-D26832C7-9249-43EC-92CE-72DA628ADFDE Q39550459-2BDD30A1-9210-46E5-B6F0-592A5E0F2AB2 Q39781545-B11A95B0-0F49-4F02-A046-F7EB2D37A7C6 Q40109317-BA8ABFF0-1E78-445F-9905-7A50B88D9B63 Q41602019-4E640A1C-9883-420A-AF05-C6167813883B Q41884542-583DC33D-C19B-413A-87AB-1499D909C0FF Q42326086-A98362F4-BB1D-42FB-A424-A6A8DDDF9947 Q43562848-4D66C989-1930-414B-9E9D-6D5F5A443470 Q43591838-75D14C2A-8246-4CC8-A4AE-8A5ADF4D3A9C Q43882361-ADEB0E35-A87F-4A50-9E1B-A1F98CB81CEF

P2860

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

Item

http://www.wikidata.org/entity/Q37358508

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 1996

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs